Enhancing Healthcare Safety through Collaboration
BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has forged a strategic partnership with ChemoGLO™, specialists in hazardous drug detection and decontamination. This collaboration aims to enhance testing procedures for hazardous drug contamination in healthcare facilities.
Revolutionary Testing Solutions
The partnership will facilitate a pioneering approach to hazardous drug contamination testing. By integrating the BD® HD Check System, which provides rapid, point-of-care results within 10 minutes, with ChemoGLO™'s advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS), health care facilities will now access comprehensive reports on a wider panel of hazardous substances.
Streamlined Processes for Safety
Once healthcare professionals collect a sample using the HD Check kit, it can be securely packaged and sent off to ChemoGLO™ for an in-depth analysis. Users can expect quantitative results within three to five days. Eric Borin, the worldwide president of BD Medication Delivery Solutions, emphasized that this innovation supports healthcare providers in quickly identifying contamination risks and reinforces their commitment to keeping healthcare workers safe.
Aligning with Industry Standards
This joint initiative is congruent with the recommendations from a notable consensus conference on hazardous drug surface contamination held in 2020, which advocated for using both qualitative and quantitative methods to ensure a safer environment for healthcare staff. Health care institutions are thus encouraged to adopt this comprehensive testing strategy.
A Mission to Protect Healthcare Workers
At the core of ChemoGLO™'s mission is the commitment to protect both employees and patients from the risks associated with hazardous drug exposure. Cara Zamboni, ChemoGLO™'s CEO, stated that this collaboration represents a significant step towards expediting action and creating a safer working environment for healthcare teams.
Discover More at Industry Events
Professionals interested in learning more about this synergistic effort between BD and ChemoGLO™ are invited to visit their booths at the upcoming American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting.
About BD
BD stands out as one of the largest global medical technology companies, committed to advancing health care through innovative solutions. With over 70,000 employees, BD invests in research that enhances patient safety and optimizes healthcare service delivery. Their efforts are directed towards improving diagnostic accuracy, refining therapeutic options, and fostering better patient outcomes worldwide.
About ChemoGLO™
ChemoGLO™ has specialized for over two decades in solutions for hazardous drug detection and management. Their cutting-edge innovations, like the ChemoGLO™ Wipe Kit, offer rapid contamination testing for multiple hazardous drugs. ChemoGLO™ continues to lead the way in safeguarding healthcare environments through reliable and effective testing methods.
Frequently Asked Questions
What is the significance of the BD and ChemoGLO™ partnership?
The partnership aims to advance hazardous drug contamination testing, enhancing safety protocols for healthcare workers and patients.
How does the BD® HD Check System work?
The BD® HD Check System provides rapid qualitative test results for hazardous drugs within just 10 minutes.
What analysis does ChemoGLO™ provide?
ChemoGLO™ employs liquid chromatography-tandem mass spectrometry (LC-MS/MS) to deliver comprehensive quantitative reports on hazardous substances.
Where can healthcare professionals learn more about this collaboration?
Interested parties can visit BD and ChemoGLO™ at their respective booths during the ASHP Midyear Clinical Meeting.
What is ChemoGLO™'s mission?
ChemoGLO™ is dedicated to providing superior safety measures against hazardous drug exposure to protect healthcare workers and patients.
